metastatic prostate cancer incidence, Northwestern Medicine study, Edward Schaeffer, Adam Weiner
Feature | Prostate Cancer | July 25, 2016
The number of new cases of metastatic prostate cancer climbed 72 percent in the past decade from 2004 to 2013, reports...
Varian, Varex Imaging Corp., components, new name, spinoff
News | Imaging | July 25, 2016
July 25, 2016 — Varian Medical Systems announced last week that Varex Imaging Corp.
ASTRO, clinical practice statement update, rectal cancer, radiation therapy
News | Radiation Therapy | July 22, 2016
The American Society for Radiation Oncology (ASTRO) recently issued a new clinical practice statement for the treatment...
PTW New York, BeamScan water phantom, radiation therapy, dosimetry, AAPM 2016
Technology | Radiation Therapy | July 21, 2016
July 21, 2016 — PTW New York announced it will display its Beamscan technology and the latest advancements in radiati
News | Clinical Decision Support | July 15, 2016
The National Comprehensive Cancer Network (NCCN), an alliance of 27 of the nation’s leading cancer centers, has been...
photoacoustic imaging

Images of prostate cells captured through photoacoustic imaging. Top: cancer cells that express the targeted cancer marker, PSMA; bottom: cells that lack PSMA. A research team led by Kent Nastiuk of Roswell Park Cancer Institute has published new evidence that this approach can be a useful tool in monitoring and selecting treatments for many cancers.

News | Prostate Cancer | July 15, 2016
While active surveillance is often recommended for patients with nonaggressive prostate cancer to reduce unnecessary...
PET, mpMRI, prostate cancer detection, targeted biopsies, University of Michigan study, Morand Piert

The figure shows a Gleason 3+4 prostate cancer (arrows) as identified on T2-weighted (A) and diffusion-weighted (B) MRI, F-18-choline PET (C), as well as PET/MRI (D).

News | Prostate Cancer | July 14, 2016
July 14, 2016 — Adding F-18-choline positron e...
prostate cancer, MRI-guided biopsies, Overlake Medical Center Washington
News | Prostate Cancer | July 13, 2016
Overlake Medical Center, Bellevue, Wash., recently announced it is formally adopting a new standard of care for...
InSightec, ExAblate Neuro, MRI-guided focused ultrasound device, essential tremor, FDA

Image courtesy of InSightec

Technology | Focused Ultrasound Therapy | July 11, 2016
The U.S. Food and Drug Administration (FDA) recently approved the first focused ultrasound device to treat essential...
News | Radiation Therapy | July 11, 2016
A new study assed the rates of laryngeal preservation and laryngectomy-free survival in patients receiving the...
Feature | Treatment Planning | July 06, 2016 | Melinda Taschetta-Millane
Treatment planning systems are at the heart of radiation therapy (RT) and the key to improved patient outcomes. Once...
IBA, Institute Curie, proton therapy, experimental research beam line, install
News | Proton Therapy | July 05, 2016
IBA (Ion Beam Applications S.A.) and the Institute Curie in Paris, France, announced the signature of an agreement for...
Accuray, Radixact Treatment Delivery Platform, image-guided radiation therapy, IGRT, FDA clearance
Technology | Image Guided Radiation Therapy (IGRT) | June 30, 2016
Accuray Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its...
blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
prostate cancer, biopsy, PET-CT, Ga-68 PSMA, SNMMI 2016 study, Wolfgang Fendler
News | PET-CT | June 20, 2016
Prostate cancer is the leading cancer among men, second only to skin cancer. With surgical removal at the frontline of...
pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

News | Radiopharmaceuticals and Tracers | June 20, 2016
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of...
News | Prostate Cancer | June 17, 2016
Decatur Memorial Hospital, Decatur, Ill., is now offering C-11 choline positron emission tomography (PET)/computed...
immunotherapy, checkpoint inhibitors, University of Chicago study, radiation therapy, vaccination
News | Radiation Therapy | June 13, 2016
June 13, 2016 — By combining local radia...
UAB, iSR'obot Mona Lisa, prostate cancer, image-guided biopsy

Jeffrey Nix, M.D., left, and Soroush Rais-Bahrami, M.D., with the iSR’obotTM Mona Lisa , a new image guided device for diagnosing prostate cancer. Image courtesy of UAB News.

News | Biopsy Systems | June 09, 2016
The University of Alabama at Birmingham (UAB) announced it is one of two beta sites in the United States that will...
Overlay Init